PPP1R13B (protein phosphatase 1 regulatory subunit 13B), also called apoptosis-stimulating protein of p53 (ASPP)1, is a member of the ASPP family of proteins, which contains three members namely, ASPP1, ASPP2 and iASPP. Its C-terminal is composed of ankyrin repeats, a SH3 domain and proline-rich sequences. The first 100 residues of its N-terminal contains RAS-association domains (RAD).
Synonyms: Anti-Apoptosis-stimulating of p53 protein 1 antibody produced in rabbit; Anti-Protein phosphatase 1 regulatory subunit 13B antibody produced in rabbit
MDL Number: MFCD08705574
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: PPP1R13B (protein phosphatase 1 regulatory subunit 13B) promotes apoptosis in cancer cells, through its interaction with p53, p63 and p73. It is also a transcriptional target of E2F protein. Inactivation of this gene by hypermethylation favors pathogenesis of gestational trophoblastic disease, which is characterized by trophoblastic lesions, such as choriocarcinomas and potentially malignant hydatidiform moles. Its promoter is also aberrantly methylated in acute lymphoblastic leukemia (ALL) resulting in its reduced expression, and this correlates to poor prognosis.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC